MedTrace Logo

The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults

NCT05761860 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-05-01

No results posted yet for this study

Summary

Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, we will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, and decision-making.

Conditions

Interventions

DRUG

OxyCODONE 5 mg Oral Tablet

Oxycodone 5mg oral administration

DRUG

OxyCODONE 2.5 mg Oral Tablet

Oxycodone 2.5mg oral administration

OTHER

Placebo oxyCODONE Oral Tablet

Oxycodone 0mg (placebo) oral administration

DRUG

Oxytocin Nasal Spray (48 IU)

Intranasal oxytocin administration (48 IU)

OTHER

Placebo Oxytocin Nasal Spray

Intranasal oxytocin placebo administration

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Florida

    lead OTHER

Principal Investigators

  • Meredith S Berry, PhD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-12
Primary Completion
2026-12-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05761860 on ClinicalTrials.gov